Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Authors

Institutions

Publication Details

Journal
The Journal of Prevention of Alzheimer s Disease
Published
2025-12-01
DOI
https://doi.org/10.1016/j.tjpad.2025.100446
Citations
1
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Rashna Khanna, Brandy R. Matthews, Dawn A. Brooks, Ivelina Gueorguieva et al.
1 citations
The Journal of Prevention of Alzheimer s Disease
Dementia and Cognitive Impairment Research
1.47
article

Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension

Rashna Khanna, Brandy R. Matthews, Dawn A. Brooks, Ivelina Gueorguieva, M Paget, Giulia Tronchin, Lars Lau Rakêt, Christophe Sapin, Emel Serap Monkul Nery, Mark A. Mintun, Shoichiro Sato, Hong Wang, Scott W. Andersen, Jennifer A. Zimmer, John R. Sims, Cynthia Evans, Paul Ardayfio, Alette M. Wessels
article en
1 citations

Abstract

No abstract available for this paper.
The Journal of Prevention of Alzheimer s DiseaseVol. 13(2)
Eli Lilly (United States) (US)
Openalex Percentile: Top 13%
Dementia and Cognitive Impairment Research
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.